Upcoming Earnings: Q2 '26
Estimated EPS
-$0.56
Estimated Rev
$0M
$AVIR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.57 down -42.50% YoY • Atea Pharmaceuticals Inc expects to report topline results for its C-BEYOND HCV trial in mid-2026 and C-FORWARD at year-end 2026, targeting March 2027 for NDA submission, with AT-587 entering Phase 1 in mid-2026.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.56 | -- | -- | N/A |
Q1 '26 | -$0.56 | -$0.57 | -2.70% | MISSED |
Q4 '25 | -$0.49 | -$0.57 | -17.53% | MISSED |
Q3 '25 | -$0.41 | -$0.53 | -27.71% | MISSED |
Q2 '25 | -$0.41 | -$0.44 | -6.02% | MISSED |